期刊文献+

Simultaneous determination of asenapine and valproic acid in human plasma using LC-MS/MS:Application of the method to support pharmacokinetic study

Simultaneous determination of asenapine and valproic acid in human plasma using LC-MS/MS:Application of the method to support pharmacokinetic study
下载PDF
导出
摘要 Combination of asenapine with valproic acid received regulatory approval for acute treatment of schizophrenia and maniac episodes of bipolar disorders. A simple LC-MS/MS method was developed and validated for simultaneous quantification of asenapine and valproic acid in human plasma. Internal standards were added to 300 ~L of plasma sample prior to liquid-liquid extraction using methyl tertiary butyl ether (MTBE). Chromatographic separation was achieved on Phenomenex C18 column (50 mm ~ 4.6 mm, 5 pm) in isocratic mode at 40 ~C. The mobile phase used was 10 mM ammonium formate-acetonitrile (5:95, v/v) at a constant flow rate of 0.8 mL/min monitored on triple quadrupole mass spectrometer, operating in the multiple reaction monitoring (MRM) mode. The injection volume used for LC-MS/MS analysis was 15 taL and the run time was 2.5 min. These low run time and small injection volume suggest the high efficiency of the proposed method. The method was validated over the concentration range of 0.1-10.02ng/mL and 10-20,000ng/mL for asenapine and valproic acid respectively. The method recoveries of asenapine (81.33%), valproic acid (81.70%), gliclazide (78.45%) and benzoic acid (79.73) from spiked plasma samples were consistent and reproducible. The application of this method was demonstrated by a pharmacokinetic study in 8 healthy male volunteers with 5 mg asenapine and 250 mg valproic acid administration. Combination of asenapine with valproic acid received regulatory approval for acute treatment of schizophrenia and maniac episodes of bipolar disorders. A simple LC-MS/MS method was developed and validated for simultaneous quantification of asenapine and valproic acid in human plasma. Internal standards were added to 300 ~L of plasma sample prior to liquid-liquid extraction using methyl tertiary butyl ether (MTBE). Chromatographic separation was achieved on Phenomenex C18 column (50 mm ~ 4.6 mm, 5 pm) in isocratic mode at 40 ~C. The mobile phase used was 10 mM ammonium formate-acetonitrile (5:95, v/v) at a constant flow rate of 0.8 mL/min monitored on triple quadrupole mass spectrometer, operating in the multiple reaction monitoring (MRM) mode. The injection volume used for LC-MS/MS analysis was 15 taL and the run time was 2.5 min. These low run time and small injection volume suggest the high efficiency of the proposed method. The method was validated over the concentration range of 0.1-10.02ng/mL and 10-20,000ng/mL for asenapine and valproic acid respectively. The method recoveries of asenapine (81.33%), valproic acid (81.70%), gliclazide (78.45%) and benzoic acid (79.73) from spiked plasma samples were consistent and reproducible. The application of this method was demonstrated by a pharmacokinetic study in 8 healthy male volunteers with 5 mg asenapine and 250 mg valproic acid administration.
出处 《Journal of Pharmaceutical Analysis》 SCIE CAS 2013年第6期394-401,共8页 药物分析学报(英文版)
关键词 ASENAPINE GLICLAZIDE PharmacokineticsBipolar disordersSchizophrenia Valproic acid Asenapine Gliclazide PharmacokineticsBipolar disordersSchizophrenia Valproic acid
  • 相关文献

参考文献1

二级参考文献29

  • 1A.A. Miller, P. Wheatley, D.A. Sawyer, et al., Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats, Epilepsia 27 (1986) 483-489.
  • 2A.F. Cohen, G.S. Land, D.D. Breimer, et al., Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans, Clin. Phar- macol. Ther. 42 (1987) 535-541.
  • 3R.A. Biddlecombe, K.L. Dean, C.D. Smith, et al., Validation of a radioimmunoassay for the determination of human plasma concentrations of lamotrigine, J. Pharm. Biomed. Anal. 8 (1990) 691 694.
  • 4M.W. Sinz, R.P. Remmel, Analysis of lamotrigine and lamotri- gine 2-N-glucuronide in guinea pig blood and urine by reserved- phase ion-pairing liquid chromatography, J. Chromatogr. 571 (1991) 217330.
  • 5S. Yamashita, K. Furuno, H. Kawasaki, et al., Simple and rapid analysis of lamotrigine, a novel antiepileptic, in human serum by high-performance liquid chromatography using a solid-phase extraction technique, J. Chromatogr. B 670 (1995) 354357.
  • 6B.C. Sallustio, R.'G. Morris, High-performance liquid chromato- graphy quantitation of plasma lamotrigine concentrations: appli- cation measuring trough concentrations in patients with epilepsy, Ther. Drug Monit. 19 (1997) 688-693.
  • 7G.L. Lensmeyer, B.E. Gidal, D.A. Wiebe, Optimized high- performance liquid chromatographic method for determinationof lamotrigine in serum with concomitant determination of phenytoin, carbamazepine, and carbamazepine epoxide, Ther. Drug Monit. 19 (1997) 292-300.
  • 8[ A. Bartoli, R. Marchiselli, G. Gatti, A rapid and specific assay for the determination of lamotrigine in human plasma by normal- phase HPLC, Ther. Drug Monit. 19 (1997) 100-107.
  • 9D. Londero, P.L. Greco, New micromethod for the determina- tion of lamotrigine in human plasma by high-performance liquid chromatography, J. Chromatogr. B 691 (1997) 139-144.
  • 10K.M. Matar, P.J. Nicholls, S.A. Bawazir, et al., A rapid liquid chromatographic method for the determination of lamotrigine in plasma, J. Pharm. Biomed. Anal. 17 (1998) 525-531.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部